Preview

July 2020

The World Health Organization (WHO) has come under fire from US President Donald Trump for its role in the Covid-19 epidemic. But, while its recent actions may be in dispute, the organization has a long history as an influential part of tackling global health issues. To find out more, we break down some of the most significant moments in the history of the WHO. Plus, explore the potential of the RECOVERY trial in the UK, a colossal public undertaking that aims to assess the anticoronavirus efficacy of existing treatments.

Also, we find out how companies are salvaging clinical trials that have been disrupted by Covid-19, take a look at how changes to intellectual property laws could impact pharma after the current pandemic subsides, and examine the challenges faced by drugs designed to target seasonal allergies.

Plus, we ask if fatty acids could hold the key to unlocking oral formulations of biologic drugs, learn why the blood-brain barrier is so difficult for drugs to penetrate, and examine a method of targeting cold tumours that is gaining serious heat.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Chloe Kent, Abi Millar, Natalie Healey, Chris Lo, John Price  
Magazine Designer | Marzia Del Gaone

Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | A cure for a costGo to article: In this issueGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NewsGo to article: NSFGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: The value of real-world evidence during the Covid-19 outbreakGo to article: Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industryGo to article: Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concernsGo to article: AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19Go to article: PhoenixGo to article: Phoenix Company InsightGo to article: The pharma industry briefingGo to article: No time to waste: repurposing drugs to tackle covid-19Go to article: How safe are simple painkillers?Go to article: Molnar Company Insight Go to article: Molnar-InstituteGo to article: Modelling the human body: a game changer for drug testing?Go to article: Pandemic pricing: existing drugs and price gougingGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Pandemic pricing: novel treatments and vaccinesGo to article: The dark side of anticoagulants: will a new approach shed light?Go to article: Zenatek Go to article: Finding a cure for HIV with ViiV Healthcare and UNC-Chapel HillGo to article: Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issueGo to article: Nelson LabsGo to article: Could nanoparticles unlock the pharmaceutical benefits of turmeric?Go to article: Why aren’t more companies automating PV data capture?Go to article: Modality SolutionsGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: ButterworthGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: MimotopesGo to article: EventsGo to article: Next issue